MedTrace Logo

Tegoprazan-containing Sequential for H. Pylori

NCT06382493 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-04-28

No results posted yet for this study

Summary

As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Tegoprazan-containing sequential H. pylori eradication therapy

tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy

DRUG

Esomeprazole-containing sequential H. pylori eradication therapy

Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Nayoung Kim, Prof. · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2026-12-12
Completion
2026-12-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06382493 on ClinicalTrials.gov